The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Genmab (GMAB) will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting neurological diseases. Some failures split up partners, and one particularly ...

Over the past decade, a shift has been occurring in biopharma R&D. Despite great advancements in drug technologies and our understanding of diseases, it is getting harder to develop new drugs and ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and ...

Advances in our understanding of cancer biology have led to the discovery of a spectrum of new therapeutic targets. However, despite remarkable progress in the identification and characterization of ...

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...